← Back to Screener
Bioventus Inc. Class A Common Stock (BVS)
Price$10.41
Favorite Metrics
Price vs S&P 500 (26W)52.23%
Price vs S&P 500 (4W)12.56%
Market Capitalization$878.11M
P/E Ratio (Annual)38.63x
All Metrics
P/CF (Annual)11.76x
Book Value / Share (Quarterly)$2.67
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)3.52%
Cash Flow / Share (Quarterly)$1.05
Price vs S&P 500 (YTD)39.29%
Gross Margin (TTM)68.33%
Net Profit Margin (TTM)4.00%
EPS (TTM)$0.33
10-Day Avg Trading Volume0.45M
EPS Excl Extra (TTM)$0.33
Revenue Growth (5Y)12.08%
EPS (Annual)$0.33
ROI (Annual)4.66%
Gross Margin (Annual)68.33%
Net Profit Margin (5Y Avg)-11.86%
Cash / Share (Quarterly)$0.74
P/E Basic Excl Extra (TTM)38.63x
Revenue Growth QoQ (YoY)2.77%
EPS Growth (5Y)2.26%
P/E Normalized (Annual)38.63x
ROA (Last FY)3.33%
Revenue Growth TTM (YoY)-0.91%
EBITD / Share (TTM)$0.83
ROE (5Y Avg)-29.59%
Operating Margin (TTM)9.44%
Cash Flow / Share (Annual)$1.05
P/B Ratio4.77x
P/B Ratio (Quarterly)3.34x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.99x
Net Interest Coverage (TTM)2.02x
ROA (TTM)3.27%
EV / EBITDA (TTM)19.97x
EPS Incl Extra (Annual)$0.33
Current Ratio (Annual)1.70x
Quick Ratio (Quarterly)1.12x
3-Month Avg Trading Volume0.34M
52-Week Price Return33.33%
EV / Free Cash Flow (Annual)15.68x
P/E Incl Extra (TTM)38.63x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$-4.10
P/S Ratio (Annual)1.55x
Asset Turnover (Annual)0.83x
52-Week High$10.57
Operating Margin (5Y Avg)-11.17%
EPS Excl Extra (Annual)$0.33
CapEx CAGR (5Y)-8.93%
26-Week Price Return56.21%
Quick Ratio (Annual)1.12x
13-Week Price Return36.26%
Total Debt / Equity (Annual)1.65x
Current Ratio (Quarterly)1.70x
Enterprise Value$1,130.464
Revenue / Share Growth (5Y)7.37%
Asset Turnover (TTM)0.82x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.06x
Pretax Margin (Annual)4.53%
Cash / Share (Annual)$0.74
3-Month Return Std Dev41.53%
Gross Margin (5Y Avg)67.00%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)11.81%
EBITDA Interim CAGR (5Y)20.04%
ROE (Last FY)12.35%
Net Interest Coverage (Annual)2.02x
EPS Basic Excl Extra (Annual)$0.33
P/FCF (TTM)9.52x
Receivables Turnover (TTM)4.44x
EV / Free Cash Flow (TTM)15.68x
Total Debt / Equity (Quarterly)1.65x
EPS Incl Extra (TTM)$0.33
Receivables Turnover (Annual)4.44x
ROI (TTM)4.54%
P/S Ratio (TTM)1.55x
Pretax Margin (5Y Avg)-15.60%
Revenue / Share (Annual)$8.24
Tangible BV / Share (Annual)$-9.45
Forward P/E13.95x
Free OCF CAGR (5Y)1.27%
Price vs S&P 500 (52W)3.50%
P/E Ratio (TTM)38.63x
Year-to-Date Return41.94%
5-Day Price Return16.04%
EPS Normalized (Annual)$0.33
ROA (5Y Avg)-6.18%
Net Profit Margin (Annual)4.00%
Month-to-Date Return15.66%
Cash Flow / Share (TTM)$-1.35
EBITD / Share (Annual)$0.82
Operating Margin (Annual)9.44%
LT Debt / Equity (Annual)1.52x
P/CF (TTM)11.76x
ROI (5Y Avg)-9.77%
P/E Excl Extra (TTM)38.63x
LT Debt / Equity (Quarterly)1.52x
EPS Basic Excl Extra (TTM)$0.33
P/B Ratio (Annual)3.34x
Inventory Turnover (TTM)2.06x
Pretax Margin (TTM)4.53%
Book Value / Share (Annual)$2.67
Price vs S&P 500 (13W)35.57%
Net Margin Growth (5Y)-4.78%
Beta0.82x
P/FCF (Annual)12.18x
Revenue / Share (TTM)$8.20
ROE (TTM)13.79%
52-Week Low$5.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.13
4.11
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
BVSBioventus Inc. Class A Common Stock | 1.55x | 12.08% | 68.33% | 9.44% | $10.41 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Bioventus Inc. is a medical technology company that develops clinically differentiated treatments enhancing natural healing processes across the orthopedic continuum. Its product portfolio serves multiple orthopedic specialties—including sports medicine, joint reconstruction, trauma, and spine surgery—organized into three verticals: Pain Treatments, Surgical Solutions, and Restorative Therapies. The company generates key revenue in the United States with growing international market presence.